162 related articles for article (PubMed ID: 11155006)
1. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
Egger B; Schmid SW; Naef M; Wildi S; Büchler MW
Dig Surg; 2000; 17(6):602-609. PubMed ID: 11155006
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium).
Haentjens P
Injury; 1996 Jul; 27(6):385-90. PubMed ID: 8881132
[TBL] [Abstract][Full Text] [Related]
3. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
[TBL] [Abstract][Full Text] [Related]
4. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Righini M; Galanaud JP; Guenneguez H; Brisot D; Diard A; Faisse P; Barrellier MT; Hamel-Desnos C; Jurus C; Pichot O; Martin M; Mazzolai L; Choquenet C; Accassat S; Robert-Ebadi H; Carrier M; Le Gal G; Mermilllod B; Laroche JP; Bounameaux H; Perrier A; Kahn SR; Quere I
Lancet Haematol; 2016 Dec; 3(12):e556-e562. PubMed ID: 27836513
[TBL] [Abstract][Full Text] [Related]
6. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.
Mahé I; Bergmann JF; d'Azémar P; Vaissie JJ; Caulin C
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):347-51. PubMed ID: 15981008
[TBL] [Abstract][Full Text] [Related]
8. [Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients].
Pavlović S; Zivković S; Koraćević G
Vojnosanit Pregl; 2007 Aug; 64(8):538-42. PubMed ID: 17874721
[TBL] [Abstract][Full Text] [Related]
9. Total knee replacement: prevention of deep-vein thrombosis using pharmacological (low-molecular-weight heparin) and mechanical (intermittent foot sole pump system) combined prophylaxis. Preliminary results.
Giannoni MF; Ciatti R; Capoccia L; Ruggiero M; Dauri M; Mariani PP
Int Angiol; 2006 Sep; 25(3):316-21. PubMed ID: 16878083
[TBL] [Abstract][Full Text] [Related]
10. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
11. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.
Blanchard J; Meuwly JY; Leyvraz PF; Miron MJ; Bounameaux H; Hoffmeyer P; Didier D; Schneider PA
J Bone Joint Surg Br; 1999 Jul; 81(4):654-9. PubMed ID: 10463739
[TBL] [Abstract][Full Text] [Related]
12. [Prevention of venous thromboembolism in polytraumatized patients. Epidemiology and importance].
Venet C; Berger C; Tardy B; Viallon A; Decousus H; Bertrand JC
Presse Med; 2000 Jan; 29(2):68-75. PubMed ID: 10682030
[TBL] [Abstract][Full Text] [Related]
13. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
Simonneau G; Laporte S; Mismetti P; Derlon A; Samii K; Samama CM; Bergman JF;
J Thromb Haemost; 2006 Aug; 4(8):1693-700. PubMed ID: 16796710
[TBL] [Abstract][Full Text] [Related]
14. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Davis R; Faulds D
Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11).
Moreno Gonzalez E; Fontcuberta J; de la Llama F
Hepatogastroenterology; 1996; 43(9):744-7. PubMed ID: 8799424
[TBL] [Abstract][Full Text] [Related]
16. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis.
Cyrkowicz A
Eur J Obstet Gynecol Reprod Biol; 2002 Jan; 100(2):223-6. PubMed ID: 11750969
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
De A; Roy P; Garg VK; Pandey NK
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M
Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
